Paclitaxel
- Generic Name
- Paclitaxel
- Brand Names
- Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H51NO14
- CAS Number
- 33069-62-4
- Unique Ingredient Identifier
- P88XT4IS4D
- Background
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
- Indication
Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
- Associated Therapies
- -
Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
- Conditions
- First Posted Date
- 2004-04-23
- Last Posted Date
- 2013-04-11
- Lead Sponsor
- Gynecologic Oncology Group
- Registration Number
- NCT00003386
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States
Combination Chemotherapy in Treating Patients With Bladder Cancer
- Conditions
- First Posted Date
- 2004-04-23
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 490
- Registration Number
- NCT00003701
- Locations
- 🇺🇸
Hahnemann University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States
🇺🇸Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
Paclitaxel With or Without Trastuzumab Following Peripheral Stem Cell Transplantation in Treating Patients With Refractory Stage IV Breast Cancer
- Conditions
- First Posted Date
- 2004-04-23
- Last Posted Date
- 2010-04-02
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT00004013
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer
- Conditions
- First Posted Date
- 2004-04-23
- Last Posted Date
- 2015-04-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 132
- Registration Number
- NCT00003880
Paclitaxel Plus Radiation Therapy in Treating Patients With Untreated Stage III Non-small Cell Lung Cancer
- Conditions
- First Posted Date
- 2004-04-22
- Last Posted Date
- 2013-05-03
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT00002519
- Locations
- 🇺🇸
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Vanderbilt Cancer Center, Nashville, Tennessee, United States
🇺🇸Sarah Cannon-Minnie Pearl Cancer Center, Nashville, Tennessee, United States
S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer
- Conditions
- Interventions
- Biological: filgrastimDrug: carboplatinDrug: cyclophosphamideDrug: carmustineDrug: doxorubicin hydrochlorideDrug: cisplatinDrug: tamoxifen citrateRadiation: radiation therapyDrug: paclitaxelDrug: thiotepaProcedure: autologous bone marrow transplantationProcedure: peripheral blood stem cell transplantation
- First Posted Date
- 2004-04-22
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 602
- Registration Number
- NCT00002772
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Paclitaxel Combined With Fluorouracil-Uracil and Leucovorin in Treating Patients With Solid Tumors
- Conditions
- First Posted Date
- 2004-04-21
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- University of Pittsburgh
- Registration Number
- NCT00009828
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Can Not Be Surgically Removed
- Conditions
- First Posted Date
- 2004-04-14
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 294
- Registration Number
- NCT00003235
- Locations
- 🇺🇸
St. Francis Medical Center, Trenton, New Jersey, United States
🇺🇸Trinitas Hospital - Jersey Street Campus, Elizabeth, New Jersey, United States
🇺🇸Community Medical Center, Toms River, New Jersey, United States
Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
- Conditions
- First Posted Date
- 2004-04-14
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- St. Barnabas Medical Center
- Target Recruit Count
- 17
- Registration Number
- NCT00003717
- Locations
- 🇺🇸
St. Barnabas Medical Center, Livingston, New Jersey, United States
🇺🇸Monmouth Medical Center, Long Branch, New Jersey, United States
S9914: Combination Chemotherapy Plus Filgrastim in Untreated Extensive-Stage Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2004-04-12
- Last Posted Date
- 2013-02-15
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 88
- Registration Number
- NCT00004137
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸CCOP - Central Illinois, Decatur, Illinois, United States
🇺🇸Veterans Affairs Medical Center - Shreveport, Shreveport, Louisiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.